Jul 31, 2025 08:30AM
Jul 11, 2025 07:30AM
Jul 11, 2025 07:30AM
Jun 2, 2025 09:29AM
Jun 2, 2025 09:29AM
May 15, 2025 07:30AM
May 15, 2025 07:30AM MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress
May 5, 2025 12:30PM
Mar 18, 2025 07:30AM
Mar 18, 2025 07:30AM
Mar 4, 2025 07:30AM
Mar 4, 2025 07:30AM
Feb 24, 2025 08:30AM
Feb 20, 2025 07:30AM MiNK Therapeutics (INKT) Regains Nasdaq Compliance
Feb 20, 2025 07:30AM
Feb 12, 2025 01:03PM
Feb 12, 2025 01:00PM
Jan 23, 2025 02:13PM
Jan 23, 2025 02:13PM
Dec 18, 2024 09:45AM
Nov 14, 2024 07:00AM MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
Nov 11, 2024 07:30AM
Apr 8, 2024 12:01PM
Apr 8, 2024 12:00PM
Mar 21, 2024 07:00AM
Mar 6, 2024 08:30AM
Mar 6, 2024 08:30AM
Feb 14, 2024 08:00AM First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
Feb 6, 2024 08:02AM
Feb 6, 2024 08:00AM
Feb 6, 2024 08:00AM
Jan 30, 2024 08:00AM
Dec 20, 2023 07:31AM
Dec 20, 2023 07:30AM
Nov 9, 2023 07:00AM MiNK Therapeutics Reports Third Quarter 2023 Results
Nov 3, 2023 12:02PM
Nov 3, 2023 12:00PM
Aug 10, 2023 07:30AM
May 22, 2023 08:30AM
May 18, 2023 08:30AM
May 18, 2023 08:30AM
Apr 18, 2023 01:33PM MiNK Therapeutics (INKT) Announces Clinical Data on agenT-797
Apr 18, 2023 01:32PM
Apr 18, 2023 01:32PM
Nov 10, 2022 09:05AM
Mar 18, 2022 08:31AM
Mar 18, 2022 08:30AM
Mar 18, 2022 08:30AM
Mar 3, 2022 04:35PM MiNK Therapeutics to Report Fourth Quarter & Full Year 2021 Financial Results and Business Update
Mar 3, 2022 09:28AM

66,407 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All